Home Blog Page 1430

Railtown AI Technologies Launches Railengine, a Real-Time Event-Based Ingestion Engine to Power Next-Generation AI Agents

By
Advertorial Desk
-
Vancouver, British Columbia – Newsfile Corp. – January 26, 2026 – Railtown AI Technologies Inc. (CSE: RAIL) (OTCQB: RLAIF) (“Railtown”, “Railtown AI”, or the “Company”) a leader in AI developer tools and agentic frameworks, is pleased to announce the launch of Railengine, its real-time, event-based ingestion engine, a core component of the Company’s end-to-end AI agent development platform (the “Platform”). Railengine allows AI agents to ingest and act on streaming data in real time, advancing beyond traditional batch processing to deliver richer, context-aware insights and responses across complex enterprise environments. Combined with Railtown’s Railtracks Agent Development Kit (ADK) and Conductr agent observability tool, Railtown has produced a platform that enables developers to build, deploy, and manage intelligent AI agents at scale.

Railengine Provides agents instant access to context-rich, searchable enterprise knowledge, enabling developers to launch advanced RAG (Retrieval-Augmented Generation) workflows, automation, and agent runs while leveraging pre-built SaaS Data Connectors for seamless integration, semantic search, and intelligent automation. www.railengine.ai.

The Railtracks ADK offers developers a Python-native framework to design, orchestrate, and deploy autonomous AI agents with prebuilt integrations, execution tracing, and orchestration tools that support real world, multi-stage agent workflows. www.railtracks.org.

Conductr Railtown’s observability tool, provides developers and operations teams with end-to-end visibility into agent behaviour, performance metrics, resource utilization, and reasoning paths enabling debugging, optimization, and secure, efficient deployments. www.conductr.ai.

“With this launch, Railtown delivers a complete Agent Development Platform, from real-time data ingestion through agent creation and observability,” said Cory Brandolini, CEO of Railtown. “The Platform equips developers with the tools to build agents that act on live data streams while giving teams the insights and controls they need to operate with confidence.”

Strategic Integration with AI Partnerships and Canadian Sovereign AI Ecosystem

Building on Railtown’s acquisition of AI Partnerships Corp., the Company expects to integrate the Platform into the AI Partnerships global affiliate ecosystem, giving more than 180 AI solution provider affiliates access to Railtown’s tools to rapidly build and deploy production-ready AI agents across industries.

This integration will support Canadian sovereign computing and secure deployment, enabling affiliates and their customers to develop Canadian truly Sovereign AI Agents that meet stringent data residency, privacy, and compliance requirements while remaining fully controlled within Canada.

Canadian Compute and Hosting

The Railtown Platform, powered by TELUS’s sovereign GPU infrastructure and Uniserve’s hosting, provides developers with a complete, Canadian-resident environment for agent development.

By leveraging high-performance Canadian infrastructure, Railtown enables affiliates and their customers to deploy truly Sovereign AI Agents that meet stringent data residency, privacy, and compliance requirements.

Canadian Companies and Developers

In the combination of Railtown’s agent development platform, TELUS’ sovereign GPU infrastructure, and Uniserve’s Canadian hosting and managed services, will provide developers across Canada an end-to-end Canadian Sovereign AI Agent Development & Deployment Service, from data ingestion and agent design to secure compute, observability, and operational deployment. This ecosystem will support enterprise, government, and partner customers looking for secure, scalable, and sovereign AI solutions without reliance on foreign compute infrastructure.

The launch and ecosystem enhance Railtown’s ability to provide a scalable, production-ready foundation for industrial grade agentic AI unlocking broad access to innovative agent technologies while reinforcing Canada’s leadership in secure AI infrastructure and innovation.

About Railtown AI Technologies

Railtown AI Technologies Inc. builds AI developer tools and agentic frameworks that power the next generation of intelligent applications. Its Platform — including real-time ingestion (Railengine), agent development frameworks (Railtracks ADK), and advanced observability (Conductr) — helps teams build, deploy, and operate AI agents with confidence and at scale.

For more information, visit www.railtown.ai.

Follow us on social media

SUBSCRIBE FOR INVESTOR NEWS
Click here to receive our latest investor news alerts.

ON BEHALF OF THE BOARD
“Cory Brandolini”
Cory Brandolini, Chief Executive Officer

INVESTOR CONTACT
Rebecca Kerswell
Investor Relations Contact
Email: investors@railtown.ai
Phone: 1-604-417-4440

This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will,” “may”, “should”, “intends”, “anticipates”, “expects” and similar expressions. All statements other than statements of historical fact included in this release, including, without limitation, statements regarding the future plans and objectives of the Company, the commencement of trading of the Company’s common shares on the CSE, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations are risks detailed from time to time in the filings made by the Company with securities regulators.

Readers are cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. As a result, the Company cannot guarantee that any forward-looking statement will materialize, and readers should not place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will only update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law.

The issuer is solely responsible for the content of this announcement.

ICP DAS-BMP at WHX Dubai 2026 Spotlights Low-Migration and Low-Friction TPU

By
Advertorial Desk
-

HSINCHU, Jan. 27, 2026 /PRNewswire/ — ICP DAS-BMP (Biomedical Polymers), a Taiwan-based manufacturer and supplier of medical-grade TPU (thermoplastic polyurethane), is pleased to announce its participation in WHX Dubai 2026 (formerly Arab Health), taking place from 9 to 12 February at the Dubai Exhibition Centre. Visitors can find the ICP DAS-BMP team at Booth S7C117.

Image by ICP DAS-BMP
Image by ICP DAS-BMP

The highlight of this year’s exhibit will be two TPU innovations addressing critical needs in medical device manufacturing: the Low-Migration Series and the Low-Friction Series.

The Low-Migration Arothane™ ARP-B20 TPU is ISO 10993 compliant and suitable for implantation up to 90 days. It minimizes additive migration during processing, helping catheters retain smooth surfaces throughout their shelf life, while offering multiple color options for flexible, customized designs.

The Low-Friction Series, engineered with an inherently smooth surface, eliminates the need for additional coatings or post-processing. Made entirely of TPU and free from PFAS or plasticizers, it delivers long-term stability without surface exudation or additive migration. Its low-friction properties suit applications requiring smooth insertion, such as nasogastric tubes with guidewires, while maintaining safety and performance during storage and use.

ICP DAS-BMP will also showcase a broad TPU portfolio for diverse medical applications. The ARP, ALP, and ALC series are suitable for devices classified as Limited (less than 24 hours), Prolonged (24 hours–30 days), and Long-term (more than 30 days) contact durations under ISO 10993-1. For radiopaque applications, ARP-B20 and ALC-B40 (qualified for 90-day implantation) and the ARP-W/WG series (40–60% tungsten) provide enhanced visibility for invasive or implantable devices. The Engineering Arothane™ EARP series, known for clarity and mechanical strength, is ideal for orthodontic components, Luer-Lock connectors, and other precision medical devices.

Together, these materials reflect ICP DAS-BMP’s commitment to advancing safer, reliable, and versatile TPU solutions, helping medical device manufacturers meet evolving healthcare needs.

About ICP DAS-BMP

ICP DAS-BMP, a leading TPU manufacturer and supplier based in Taiwan, is ISO 13485 certified and operates specialized laboratories focused on quality management. Leveraging over thirty years of industrial automation expertise from its parent company ICP DAS, ICP DAS-BMP employs smart factory practices to enhance product quality and expedite delivery times. The company is committed to responsive after-sales support and flexible solutions, even for small order quantities, ensuring customer satisfaction and fostering long-term partnerships.

For more information, please visit: https://bmp.icpdas.com

New “MedTech Advance” Sourcing Directory Launches to Streamline Global Medical Device Manufacturing

By
Advertorial Desk
-

Comprehensive e-book accelerates product development by connecting R&D and procurement teams with global suppliers.

TAICHUNG, Jan. 27, 2026 /PRNewswire/ — Today marks the official release of MedTech Advance, a comprehensive digital buyer’s directory engineered to accelerate the sourcing process for the medical technology industry. As the complexity of medical device design increases, MedTech Advance provides a centralized platform for Engineering, R&D, and Procurement professionals to discover elite suppliers and high-precision components.

MedTech Advance - sourcing medtech design and manufacturing suppliers
MedTech Advance – sourcing medtech design and manufacturing suppliers

“Speed-to-market is the primary challenge in MedTech today,” said Nick Yang, Manager of MedTech Advance. “We’ve built MedTech Advance to remove the friction from procurement, providing a vetted roadmap of partners capable of meeting the industry’s rigorous regulatory and technical demands.”

Featured Contributor: Protolis

The 2026 edition highlights specialized capabilities from industry leaders such as Protolis, a premier provider of rapid prototyping and low-volume manufacturing. Protolis brings critical expertise to the directory, offering high-precision plastic and metal components specifically for the life sciences sector.

By featuring contributors like Protolis—who utilize ISO 13485-certified processes and advanced technologies such as CNC machining, vacuum casting, and injection molding—MedTech Advance ensures that R&D teams can find partners capable of delivering functional prototypes and end-use parts that meet strict tolerances and aesthetic excellence.

Global Trade Show Distribution

The directory will receive massive international exposure through 2026, with distribution confirmed for the world’s leading medical trade fairs, including:

  • MEDICA & COMPAMED (Germany)
  • MD&M Series (USA)
  • Medtec Japan & Medtec China

The e-book is designed for high-impact roles in Engineering, R&D, Procurement, Quality Assurance, and Executive Management, serving the global medical device supply chain.

About MedTech Advance

MedTech Advance is a premier digital resource and global buyer’s directory dedicated to the medical device design and manufacturing industry. By providing a curated ecosystem of world-class suppliers, it empowers professionals to accelerate product development and optimize their supply chains.

Explore the e-book at medicaex.com

About Protolis

Protolis is a specialized rapid prototyping and low-volume manufacturing company, delivering high-precision plastic and metal components for the medical and life sciences industries. We combine advanced technologies such as CNC machining, vacuum casting, injection molding, and sheet metal fabrication to produce functional prototypes, small series, and end-use parts with exceptional quality and compliance. Our expertise extends to custom medical device enclosures, housings, and components requiring aesthetic excellence, strict tolerances, and ISO 13485-certified processes.

Learn more at protolis.com

REALTY ONE GROUP CELEBRATES 20 YEARS OF COMMUNITY IMPACT, REPORTS STRONG 2025 GIVING RESULTS

By
Advertorial Desk
-

LAGUNA NIGUEL, Calif., Jan. 27, 2026 /PRNewswire/ — Realty ONE Group International, a modern, purpose-driven lifestyle brand and one of the fastest-growing real estate franchisors in the world, today proudly announced its 2025 year-end giving results, highlighting the significant impact made by its real estate professionals around the globe, through ONE Cares, the company’s charitable foundation.

In 2025, the ONE Family Network supported 240,292 community neighbors, contributed 8,467 community service hours, and donated nearly $400,000 through ONE Cares initiatives, demonstrating the brand’s ongoing commitment to service, generosity, and community leadership.

“Giving back is not an initiative at Realty ONE Group, it’s the foundation of our 6C’s, our beliefs and our values,” said Kuba Jewgieniew, CEO and Founder of Realty ONE Group International. “Our professionals are committed to making a difference, not just in real estate, but in the communities they serve every day.”

Every year, Realty ONE Group International celebrates its founding on May 1 with a global day of giving and volunteering. That special day this year impacted nearly 60,000 lives with 3,053 volunteer hours and $144,785.

Reinforcing its commitment to sustainability, Realty ONE Group International pledged 1,069 trees in 2025, advancing its ONE Tree, ONE World initiative to nearly 142,000 trees pledged worldwide since 2022.

As the company continues to grow globally, Realty ONE Group remains focused on building a legacy defined by impact, purpose, and generosity.

Realty ONE Group International’s continued success is driven by its proprietary business systems, comprehensive coaching and support, bold lifestyle brand, and a people-first COOLTURE® that differentiates it from traditional real estate models. With more than 20,000 real estate professionals across 450+ locations in nearly 30 countries and territories, the brand continues to expand its global footprint while staying true to its mission of changing lives through real estate.

Learn more at www.OwnAOne.com or www.realtyonegroup.com

About Realty ONE Group International

Realty ONE Group International is one of the fastest growing, modern, purpose-driven lifestyle brands in real estate whose ONE Purpose is to open doors across the globe – ONE home, ONE dream, ONE life at a time. The organization has rapidly grown to more than 20,000 real estate professionals in over 450 locations across nearly 30 countries and territories because of its proven business model, full-service brokerages, dynamic COOLTURE, superior business coaching through ONE University, outstanding support and its proprietary technology, zONE. Realty ONE Group International has been named the number ONE real estate brand by Entrepreneur Magazine for three consecutive years and continues to surge ahead, opening doors, not only for its clients but for real estate professionals and franchise owners. To learn more, visit www.RealtyONEGroup.com.

Heartbeats Shareholder Mr Lu Min Yong Honoured as “Global Chinese Role Model” at the 2026 Spring Festival Gala Evening

By
Advertorial Desk
-

SYDNEY and BEIJING, Jan. 27, 2026 /PRNewswire/ — Heartbeats proudly congratulates its shareholder, Lu Min Yong, on being awarded the title of “全球华人楷模” (Global Chinese Role Model) at the Global Chinese Spring Festival Gala Evening held as part of the 2026 Chinese New Year celebrations in Beijing, China.

This honour recognises Mr Yong’s exceptional contribution to business leadership, cross-border collaboration, and nation-building infrastructure, most notably through his leadership of CREGA Australia Pty Ltd, which played a critical role in Australia’s landmark Sydney Western Harbour Tunnel.

Through CREGA’s partnership with global engineering leaders, Mr Yong helped deliver some of the most advanced large-diameter tunnel boring machines ever deployed in the Southern Hemisphere. These achievements not only set new technical benchmarks for Australian infrastructure, but also demonstrated how precision engineering, long-term vision, and international cooperation can deliver projects of national significance. The Harbour Tunnel project stands as a defining example of Mr Yong’s ability to translate ambition into execution at the highest level.

Beyond infrastructure, Mr Yong’s story is also one of personal discipline and deep respect for science. Now in his 70s, he continues to lead and oversee multiple large-scale businesses across property, engineering, hospitality, sport, green technology, and health. He has never viewed age as a signal to slow down, because, in his words, success is sustained not by time, but by vitality.

This belief is what naturally connects Mr Yong to Heartbeats AU Pty Ltd. As a strong advocate of evidence-based thinking, he sees health not as a lifestyle trend, but as strategic infrastructure for human performance. The philosophy behind Heartbeats, adding life into years, not just years into life resonates deeply with his own experience. It is this foundation of physical resilience, mental clarity, and purpose that enables him to remain fully engaged, decisive, and forward-looking well beyond the age when many consider retirement.

Heartbeats was founded by Professor Hosen Kiat, one of the world’s most highly cited clinical cardiologists, to translate rigorous medical science into practical, everyday guidance for long-term health and longevity. Mr Yong’s support reflects a shared conviction: that the next era of leadership whether in infrastructure, business, or society will be defined by those who understand health as the ultimate enabler of sustained impact.

“True longevity is not about stepping back,” Mr Yong said. “It is about having the capacity, physically and mentally to continue building, contributing, and leading. Heartbeats represents that philosophy grounded in science.”

As Heartbeats continues to expand its global education and preventive health initiatives, Mr Lu Min Yong’s journey from delivering nation-shaping infrastructure to championing human longevity stands as a powerful example of how science, purpose, and endurance can shape a life without limits.

Innovent Announces IBI3003 (GPRC5D/BCMA/CD3 Trispecific Antibody) Receives Fast Track Designation from the U.S. FDA for Relapsed or Refractory Multiple Myeloma

By
Advertorial Desk
-

SAN FRANCISCO and SUZHOU, China, Jan. 27, 2026 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic, and other major diseases, announced that its anti-GPRC5D/BCMA/CD3 tri-specific antibody IBI3003 has received Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA). This designation applies to the treatment of relapsed or refractory multiple myeloma, (R/R MM) in patients who have received four or more lines of previous anti-myeloma therapies, that include at least a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 monoclonal antibody.

IBI3003 was discovered and developed using Innovent’s proprietary Sanbody® platform and its development is being advanced globally. IBI3003 is currently undergoing a Phase 1/2 clinical trial in patients with relapsed or refractory multiple myeloma in China and Australia, and there are plans to initiate a Phase 1/2 clinical trial in the United States imminently.

Clinical data presented at the American Society of Hematology (ASH) Annual Meeting on December 7, 2025[Link], demonstrated a tolerable safety profile and promising efficacy signals for IBI3003 in patients who had failed ≥2 prior lines of myeloma therapy:

  • Thirty-nine patients with R/R MM who had previously received at least a PI, an IMiD, and an anti-CD38 monoclonal antibody were treated with IBI3003 at dose levels ranging from 0.1 μg/kg to 800 μg/kg and underwent at least one tumor assessment after baseline. As of the data cutoff date of November 7, 2025, the median follow-up duration was 3.25 months (range: 0.4–7.4), and the median treatment duration was 12.14 weeks (range: 1.0–33.0).
  • Among patients treated at doses ≥120 μg/kg (n=24), the overall response rate (ORR) was 83.3%, including 4 stringent complete responses (sCR), 7 very good partial responses (VGPR), and 9 partial responses (PR). In this cohort, the ORR was 80% among 10 patients with extramedullary disease (EMD) and 77.8% among 9 patients previously treated with BCMA- and/or GPRC5D-directed therapies. Among patients who achieved complete response or better, the minimal residual disease (MRD) negativity rate was 100% (n=4), as assessed by validated next generation sequencing, with a threshold of 10-5, performed at a central laboratory.
  • All cases of cytokine release syndrome (CRS) were Grade 1-2, with only 2 cases of Grade 1-2 immune effector cell-associated neurotoxicity syndrome (ICANS) reported. Most treatment-emergent adverse events (TEAEs) related to GPRC5D targeting, including those affecting the oral cavity, skin, and nails, were Grade 1–2, with two patients experiencing Grade 3 rash.

Dr. Hui Zhou, Chief R&D Officer of Oncology in Innovent, stated, “IBI3003 monotherapy has demonstrated encouraging efficacy and a favorable safety profile in R/R MM patients who had received three or more prior lines of therapy. Notably, meaningful clinical activity was observed even in high-risk patients with EMD or those previously treated with anti-BCMA and/or GPRC5D-targeted therapies, highlighting IBI3003’s potential to address key unmet needs. Its overall manageable safety profile further supports continued investigation and the potential for durable survival benefit. The Fast Track Designation granted by the U.S. FDA represents an important milestone in the global development of IBI3003, and we look forward to further evaluating its potential to benefit patients worldwide.”

Fast Track Designation is intended to facilitate the development and expedite the review of drugs that treat serious conditions and address unmet medical needs. Programs granted FTD benefit from more frequent interactions with the FDA, which may accelerate clinical development and regulatory review.

About IBI3003 (Anti-GPRC5D/BCMA/CD3 Trispecific Antibody)

IBI3003 is a tri-specific TCE developed using Innovent’s proprietary Sanbody® platform to target both GPRC5D and BCMA. The molecule is designed to mitigate tumor escape associated with single-antigen targeting. In preclinical studies, IBI3003 demonstrated superior in vitro and in vivo antitumor activity compared with marketed benchmark T-cell engagers, including in cell lines and xenograft models with low BCMA and GPRC5D expression. A Phase 1/2 clinical trial (NCT06083207) is ongoing in China and Australia. In December 2025, IBI3003 received IND approval from the U.S. FDA, enabling initiation of a Phase 1/2 clinical trial in the United States.

About Multiple Myeloma

Multiple myeloma (MM) is a malignant hematologic disease characterized by the clonal proliferation of plasma cells and is the second most common hematologic malignancy [1]. MM remains incurable, and factors such as inadequate depth of response, extramedullary involvement, and short remission duration are associated with poor prognoses [2]. For patients with R/R MM who have received four or more prior lines of therapy, including exposure to PIs, IMiDs, and anti-CD38 antibodies, treatment options include, but are not limited to, BCMA-targeted CAR-T therapies and bispecific antibodies targeting CD3×BCMA or CD3×GPRC5D. However, the benefits of these approaches may be limited by antigen loss and treatment resistance [3].

About Innovent

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 18 products in the market. It has 4 assets in Phase 3 or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Lilly, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center.

Guided by the motto, “Start with Integrity, Succeed through Action” Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

Statement: Innovent does not recommend the use of any unapproved drug (s)/indication (s).

Forward-Looking Statements

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent’s competitive environment and political, economic, legal and social conditions.

Innovent, the Directors and the employees of Innovent assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.

References:

[1] Wang S, Xu L, Feng J, et al. Prevalence and Incidence of Multiple Myeloma in Urban Area in China: A National Population-Based Analysis. Front. Oncol. 2019;9:1513.

[2] Chinese Hematology Association, Chinese Society of Hematology. [Guidelines for the diagnosis and management of multiple myeloma in China (2022 revision)]. Zhonghua Nei Ke Za Zhi. 2022;61(5):480-487.

[3] Li C, Wang D, Song Y, et al. CT103A, a novel fully human BCMA-targeting CAR-T cells, in patients with relapsed/refractory multiple myeloma: Updated results of phase 1b/2 study (FUMANBA-1). J. Clin. Oncol. 2023;41(16_suppl):8025-8025.

 

Reeracoen Study Finds Malaysian Employers Taking a More Targeted Approach to Hiring in 2026

By
Advertorial Desk
-

Tighter labor market and rising costs prompt shift toward skills-aligned recruitment

KUALA LUMPUR and PENANG, Malaysia, Jan. 27, 2026 /PRNewswire/ — Reeracoen Malaysia has released its Hiring Trends Year-on-Year Comparison 2024 vs. 2025, showing that while Malaysian employers continued to hire in 2025, recruitment strategies are becoming more selective, disciplined, and aligned with long-term workforce needs. Employers are shifting away from broad recruitment drives toward more selective, skills-aligned hiring that supports long-term workforce sustainability.

The change comes as organisations navigate higher employment costs, ongoing skills mismatches, and tighter labour market conditions. Rather than scaling back hiring, the findings suggest a recalibration—a move toward hiring the right talent at the right time, not simply expanding headcount.

Report overview: Comparing Hiring Patterns Across Two Years

The annual study analyses hiring data across Malaysian industries, comparing actual recruitment outcomes in 2024 with employers’ hiring intentions and behaviours in 2025.

While demand for talent remains strong, employers are moving away from large hiring waves. Instead, they are implementing phased, targeted recruitment plans that prioritise roles essential to productivity and business growth. This shift reflects a broader recognition that talent acquisition is a strategic function, not just an operational task.

Why Employers Are Rethinking Hiring Approaches

The report identifies several key factors driving this shift. Rising labour costs, including wage adjustments under Budget 2025, combined with ongoing skills mismatches, have made each hiring decision more significant. Meanwhile, talent shortages in specialized and technical roles increase the risks and costs associated with hiring errors.

Despite these pressures, overall hiring demand remains stable, with employers focusing resources on roles that directly support productivity and growth.

In response, employers are re-evaluating how, when, and whom they hire. Job readiness, relevant experience, and long-term fit are now taking precedence over volume. Market benchmarking and robust candidate assessments are becoming standard tools in the hiring process.

Yohei Yagi, Country Manager at Reeracoen Malaysia, noted that this evolution is evident across multiple sectors.

“Malaysian employers are still hiring, but they’re doing so with greater precision than in previous years,” Yagi said. “Higher employment costs and ongoing skills gaps mean organisations need to be more deliberate in their hiring decisions. What we are seeing is a shift toward well-defined, skills-aligned hiring rather than broad expansion.”

Why the Report Matters for Employers

The study positions recruitment as a strategic lever that directly influences organisational resilience and competitiveness. The stakes are higher than ever: a single mis-hire can affect productivity, team dynamics, and long-term cost efficiency.

Kenji Naito, Group Chief Executive Officer of Reeracoen Group, said this growing awareness is shaping recruitment across the region.

“Across Asia-Pacific, employers are navigating tighter labour markets and rising workforce costs at the same time,” Naito said. “In Malaysia, this has led to a more disciplined approach to hiring, where accuracy and long-term fit matter more than speed or volume. Recruitment partners play an important role in helping organisations interpret market conditions and make informed, sustainable hiring decisions.”

Reeracoen developed the Hiring Trends Comparison as an annual study to help business leaders and HR professionals respond to shifting market conditions with clarity and confidence. The report provides actionable insights and benchmarks to guide more strategic workforce planning.

For employers, success in 2026 will increasingly depend on the ability to hire the right skills at the right time, supported by accurate market data and informed recruitment strategies.                        

To access the full report and explore Reeracoen Malaysia’s hiring insights and recruitment solutions, please visit: https://www.reeracoen.com.my.

About Reeracoen Malaysia

Reeracoen Malaysia is part of Reeracoen Group, an award-winning leader in Asia’s recruitment landscape, connecting top-tier talent with forward-thinking organisations. With nine offices across six major Asian countries, Reeracoen combines deep local expertise with cross-border hiring capabilities to help businesses grow stronger and faster. We uphold the highest standards of professionalism and service quality, delivering innovative and trusted recruitment solutions that meet the evolving needs of today’s workforce.

WireBarley Partners with LAFC in First Deal for Korean Fintech

By
Advertorial Desk
-

SEOUL, South Korea, Jan. 27, 2026 /PRNewswire/ — Global fintech company WireBarley has announced a multi-year strategic partnership with Los Angeles Football Club (LAFC), becoming the club’s Official Remittance Partner and the first Korean fintech company to partner with a Major League Soccer team.

Larry Freedman, Co-President of Los Angeles Football Club (LAFC), and Yoonha Lina Jeon, CMO and North America Managing Director of WireBarley.
Larry Freedman, Co-President of Los Angeles Football Club (LAFC), and Yoonha Lina Jeon, CMO and North America Managing Director of WireBarley.

The collaboration unites two brands built on global connectivity, trust, and community. As one of Major League Soccer’s most internationally recognized clubs, LAFC embodies the diverse, global culture of Los Angeles—an identity that closely aligns with WireBarley’s mission to make cross-border money transfers more accessible, transparent, and reliable for people around the world.

WireBarley specializes in connecting customers across Asia-Pacific markets—including Korea, Australia, New Zealand, Hong Kong SAR, and Vietnam—with North America. Now through its LAFC partnership, the company aims to build stronger connections with Asian American communities in the U.S. while gaining visibility among the team’s globally connected fans.

As part of the partnership, WireBarley will receive marketing rights within Los Angeles and designated international territories, along with digital and social integrations designed to engage fans through compelling content, sweepstakes, and matchday experiences. The collaboration will emphasize shared values of innovation, inclusivity, and global perspective—core pillars for both organizations.

“We are extremely excited to partner with WireBarley given their focus on connecting people from various countries and spanning different cultures,” said LAFC Co-President Larry Freedman. “Playing in Los Angeles, a city that serves as one of the most globally connected cities in the world, this was a natural fit as we seek to reflect the identity of our fanbase.”

The partnership further strengthens LAFC’s growing portfolio of international and technology-driven partners, reinforcing the club’s position at the intersection of sport, culture, and global community. 

“We are honored to partner with LAFC, a club renowned for its excellence and dedication to fans,” John Joongwon Yoo, CEO and Co-founder of WireBarley. “This partnership extends beyond the pitch to connect communities and create meaningful experiences. It will bring fans in Los Angeles and our global customers in countries including Korea, Australia, and beyond closer to LAFC through engaging matchday and interactive online experiences that celebrate the club’s spirit and passion.”

WireBarley provides international remittance services across 46 countries, with operations in seven key markets: Korea, the U.S., Canada, Australia, New Zealand, Vietnam, and Hong Kong SAR (temporarily suspended). The company has recorded over 2.2 million app downloads and 1.1 million registered users worldwide, establishing itself as a leading digital remittance platform in the Asia-Pacific region.

1...1,4291,4301,431...6,708Page 1,430 of 6,708